Boryung lands $277 million seven-year Taxotere supply contract with China
South Korean drugmaker Boryung secured a seven-year, $277 million agreement to supply the cancer drug Taxotere to China's Yifan Pharmaceutical.
Boryung announced a seven-year supply agreement with Yifan Pharmaceutical of China, worth $277 million, for the chemotherapy agent Taxotere. This contract is the Korean company's biggest supply deal so far and its first significant post-acquisition transaction after buying Taxotere's worldwide rights from Sanofi for up to 280 billion won. The arrangement mandates annual minimum purchases and includes compensation clauses if volumes fall below the agreed level, providing Boryung with predictable revenue streams.
By locking in demand from China, the largest market for the acquired portfolio, Boryung aims to prove its model of acquiring global brands, internalising production, and enhancing export value. Chief strategy officer Kim Sung-jin highlighted that the deal goes beyond mere product export, securing long-term demand and supply foundations. The company targets over 300 billion won in annual global revenue by 2030 through brand acquisitions, manufacturing transfers and growth of its contract development and manufacturing business.
Why it matters
The contract gives Boryung steady revenue and marks its entry into the Chinese oncology market, a key step in its global expansion plan.
In this story
